S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

$1.66
+0.01 (+0.61%)
(As of 03/28/2024 ET)
Today's Range
$1.64
$1.68
50-Day Range
$1.59
$1.74
52-Week Range
$0.98
$11.30
Volume
104,273 shs
Average Volume
325,006 shs
Market Capitalization
$55.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.14

Reneo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.88 Rating Score
Upside/​Downside
992.6% Upside
$18.14 Price Target
Short Interest
Bearish
12.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Reneo Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.36) to ($0.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

791st out of 938 stocks

Pharmaceutical Preparations Industry

362nd out of 425 stocks

RPHM stock logo

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

RPHM Stock Price History

RPHM Stock News Headlines

Reneo Pharmaceuticals: Q4 Earnings Insights
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Reneo Pharmaceuticals, Inc. (RPHM)
Reneo Pharmaceuticals, Inc. (RPHM)
Reneo Pharmaceuticals Inc (RPHM)
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Reneo Pharmaceuticals just downgraded at BofA, here's why
5 Analysts Have This to Say About Reneo Pharmaceuticals
Reneo Pharmaceuticals just downgraded at Piper Sandler, here's why
Reneo Pharmaceuticals just downgraded at Leerink, here's why
Reneo: Mavodelpar Data Expected December Of 2023
See More Headlines
Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RPHM
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.14
High Stock Price Target
$35.55
Low Stock Price Target
$3.00
Potential Upside/Downside
+992.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.88
Research Coverage
8 Analysts

Profitability

Net Income
$-51,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.08 per share

Miscellaneous

Free Float
27,349,000
Market Cap
$55.30 million
Optionable
Optionable
Beta
0.23
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

RPHM Stock Analysis - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" RPHM shares.
View RPHM analyst ratings
or view top-rated stocks.

What is Reneo Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12 month price objectives for Reneo Pharmaceuticals' shares. Their RPHM share price targets range from $3.00 to $35.55. On average, they expect the company's share price to reach $18.14 in the next twelve months. This suggests a possible upside of 992.6% from the stock's current price.
View analysts price targets for RPHM
or view top-rated stocks among Wall Street analysts.

How have RPHM shares performed in 2024?

Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of the year. Since then, RPHM stock has increased by 3.7% and is now trading at $1.66.
View the best growth stocks for 2024 here
.

When is Reneo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our RPHM earnings forecast
.

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its earnings results on Monday, March, 27th. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.03.

When did Reneo Pharmaceuticals IPO?

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Reneo Pharmaceuticals' major shareholders?

Reneo Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Octagon Capital Advisors LP (6.75%), BML Capital Management LLC (3.95%), Highbridge Capital Management LLC (3.37%), Vestal Point Capital LP (1.20%), GSA Capital Partners LLP (0.28%) and Goldman Sachs Group Inc. (0.19%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal.
View institutional ownership trends
.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPHM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners